Drug profile

The FDA adverse-event record for Unspecified Sedation

47 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unspecified Sedation. Species, reactions, and outcomes follow.

#1167 of 2,679
by report volume (all drugs)
47
adverse-event reports
19.1%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Unspecified Sedation ranks #1156 of 2679 by total reports (47). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1156
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Unspecified Sedation has 47 reports now versus 47 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Unspecified Sedation changes

Signature read: Unspecified Sedation's 19.1% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
47
Total Reports
9
Deaths Reported
19.1%
Death-coded share of reports

Active Ingredients

Unspecified Sedation

Administration Routes

UnknownIntravenous

Species Affected

Dog 35
Cat 10
Horse 2

Most Affected Breeds

Retriever - Labrador 4
Domestic Shorthair 3
Retriever - Golden 3
Shepherd Dog - German 3
Rottweiler 3
Bulldog - American 2
American Pit Bull Terrier 2
Rex - Devon 2
Sheepdog - Shetland 2
Schnauzer - Miniature 1

Most Reported Reactions

Vomiting 12
Diarrhoea 11
Death 6
Anorexia 6
Not eating 5
Lethargy (see also Central nervous system depression in Neurological) 5
Vocalisation 4
Lethargy (see also Central nervous system depression in 'Neurological') 4
Elevated alanine aminotransferase (ALT) 4
Weight loss 4
Seizure NOS 4
Neutrophilia 4

Outcome Breakdown

Ongoing
17 (36.2%)
Outcome Unknown
13 (27.7%)
Died
9 (19.1%)
Recovered/Normal
7 (14.9%)
Recovered with Sequela
1 (2.1%)

Unspecified Sedation: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Unspecified Sedation (#1167 of 2,679 by report volume); death-coded 19.1%. PlainBreed drug row · death-coded share stamp 19.1% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →